<DOC>
	<DOCNO>NCT00903006</DOCNO>
	<brief_summary>The goal clinical research study learn tolerable effective dos drug MK-0646 give combination Sprycel ( dasatinib ) Faslodex ( fulvestrant ) patient hormone receptor-positive metastatic breast cancer . The safety drug study well marker tumor may help researcher predict tumor ' reaction treatment .</brief_summary>
	<brief_title>Trial Fulvestrant , MK-0646 , Dasatinib Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer</brief_title>
	<detailed_description>The Study Drugs : Fulvestrant design block estrogen help breast cancer tumor cell grow . By block estrogen , may stop tumor growth . Dasatinib design change function gene . By change function gene , may prevent cancer grow spread . MK-0646 design block protein help breast cancer cell grow . By block protein , may cause cancer cell die . Study Procedures : You fine needle aspiration core needle biopsy start study treatment 2 week . These biopsy study gene protein , see change treatment . Study Groups : If find eligible take part study : enrolled Phase I Phase II study , depend join study . If Phase I , assign either Group 1 , 2 , 3 , 4 . If Phase II , ( base result screen biopsy ) randomly assign ( roll dice ) either Group 1 , 2 , 3 , 4 : - Group 1 receive fulvestrant . - Group 2 receive fulvestrant dasatinib . - Group 3 receive fulvestrant MK-0646 . - Group 4 receive fulvestrant , MK-0646 , dasatinib . All participant receive dose level fulvestrant . If Groups 2 , 3 , 4 , dose MK-0646 and/or dasatinib receive depend join study . The first set participant group receive low dose level MK-0646 and/or dasatinib . Each new set receive high dose MK-0646 and/or dasatinib set , intolerable side effect see . This continue high tolerable dose MK-0646 and/or dasatinib find . This call Phase I portion study . If enrol Phase II portion study , receive dasatinib dose tolerate Phase I portion . Study Drug Administration : Every 28 day make 1 study cycle . You receive fulvestrant needle muscle Days 1 15 Cycle 1 Day 1 Cycles 2 beyond . You 2 injection time 2 different muscle . If Group 3 Group 4 , receive MK-0646 needle vein weekly . If Group 2 Group 4 , take capsule dasatinib mouth every day study . You take drug time day cup ( 8 ounce ) water . The study staff give card must record every time take dasatinib . Study Visits : On Day 1 every cycle first 4 cycle , every 3 cycle , follow test procedure perform : - You physical exam , include measurement weight . - Your performance status record . - You ask drug may take . - Blood ( 1 tablespoon ) drawn routine test see immune system may respond study drug . On Day 1 cycle , follow procedure perform : -You ask side effect may . On Day 1 Cycle 1 , vital sign measure . On Days 8 22 Cycle 1 , vital sign weight measure . You ECG . On Day 15 Cycle 1 , follow test procedure perform : - Your vital sign weight measure . - You ECG . - You PET scan - You core needle biopsy ( remove tissue ) and/or fine needle aspiration ( small needle ) . On Days 1 , 8 , 15 , 22 Cycles 2 beyond , weight measure . On Day 1 Cycle 4 every 3 cycle , CT scan chest , abdomen and/or pelvis , check status disease . If disease spread , may also bone scan and/or x-rays bone . If take warfarin prevent abnormal blood clotting , blood ( 1-2 teaspoon ) draw check blood clot function least 1 time week blood clot function become stable . After , blood ( 1-2 teaspoon ) continue draw check blood clot function often doctor decides need . Length Study : You may receive study therapy either experience intolerable side effect disease get bad ; take study . End-of-Study Visit : After study , end-of-study visit . At visit , follow test procedure perform : - You physical exam , include measurement vital sign weight . - You ask drug may take side effect may . - Your performance status record . - Blood ( 2 teaspoon ) collect routine test . - You hear test receive MK-0646 . Four ( 4 ) , 8 , 12 week last dose study drug , blood ( 1 tablespoon ) drawn see immune system may respond study drug . This investigational study . MK-0646 FDA-approved commercially available . At time , MK-0646 use research . Fulvestrant currently FDA -approved commercially available treatment metastatic breast cancer post-menopausal woman . Dasatinib FDA-approved commercially available treat chronic myeloid leukemia . At time , use dasatinib breast cancer patient investigational . Up 40 patient take part study University Texas ( UT ) MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . For Phase I : Patients histologically cytologically confirm diagnosis metastatic hormone receptorpositive HER2negative breast cancer receive one line endocrine therapy metastatic disease . 2 . Measurable disease Response Evaluation Criteria In Solid Tumors ( RECIST ) evaluable disease ( e.g. , bone metastasis , lesion fulfill RECIST criterion metastatic disease ) 3 . Age &gt; /= 18 year 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 5 . Required laboratory value : Absolute neutrophil count ( ANC ) &gt; /= 1500 cells/mm^3 , platelet count &gt; /= 100,000 cells/mm^3 , hemoglobin &gt; /= 9 gm/L ; bilirubin &lt; /= 1.5 * upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; /= 2.5 * ULN ; serum creatinine &lt; /= 2.0 * ULN 6 . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return required assessment . 7 . Patients must postmenopausal ( &gt; 12 month amenorrhea , bilateral oophorectomy ) . 8 . Patients must receive prior antiestrogen therapy adjuvant setting . 9 . Patients may easily accessible tumor biopsy ( confirm interventional radiology ) . 10 . Patients must consent biopsy . 11 . For Phase II : Patients histologically cytologically confirm diagnosis metastatic hormone receptorpositive , HER2negative , breast cancer receive one line endocrine therapy metastatic disease . 12 . Measurable disease RECIST evaluable disease ( e.g. , bone metastasis , lesion fulfill RECIST criterion metastatic disease ) 13 . Age &gt; /= 18 year 14 . ECOG performance status &lt; /= 2 15 . Required Laboratory Values : ANC &gt; /= 1500 cells/mm^3 , platelet count &gt; /= 100,000 cells/mm^3 , hemoglobin &gt; /= 9 gm/L , Bilirubin &lt; /= 1.5 * ULN , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; /= 2.5 * ULN 16 . Serum creatinine &lt; /= 2.0 * ULN 17 . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return required assessment . 18 . Patients must postmenopausal ( &gt; 12 month amenorrhea , bilateral oophorectomy ) . 19 . Patients must receive prior antiestrogen therapy adjuvant setting . 20 . Patients may easily accessible tumor biopsy ( confirm interventional radiology ) . 21 . Patients must consent biopsy . 1 . For Phase I : History prior malignancy within past 5 year exception curatively treat basal squamous cell carcinoma skin carcinoma situ cervix 2 . Concurrent severe uncontrolled medical disease ( i.e. , systemic infection , diabetes , hypertension , coronary artery disease , congestive heart failure , ongoing recent gastrointestinal bleed , hepatic cardiac compromise , hypocalcemia , know platelet function abnormality ) . 3 . Concomitant medication know prolong QT interval , unless discontinue &gt; /= 7 day start dasatinib therapy . 4 . Newly diagnose ( within 3 month enrollment ) poorly control ( define fast serum glucose &gt; 160 mg/dl hemoglobin A1c &gt; 8 % screening ) , type 1 2 diabetes mellitus . 5 . Active untreated brain metastasis 6 . Pleural pericardial effusion grade 7 . Bone metastases 8 . Patients endocrine therapy appropriate ( i.e . life threaten metastatic disease ) . 9 . Patients require therapeutic anticoagulation ( Warfarin 1 mg port maintenance allow ) . 10 . For Phase II : History prior malignancy within past 5 year exception curatively treat basal squamous cell carcinoma skin carcinoma situ cervix 11 . Concurrent severe uncontrolled medical disease ( i.e. , systemic infection , diabetes , hypertension , coronary artery disease , congestive heart failure , ongoing recent gastrointestinal bleed , hepatic cardiac compromise , hypocalcemia , know platelet function abnormality ) . 12 . Concomitant medication know prolong QT interval , unless discontinue &gt; /= 7 day start dasatinib therapy . 13 . Newly diagnose ( within 3 month enrollment ) poorly control ( define fast serum glucose &gt; 160 mg/dl hemoglobin A1c &gt; 8 % screening ) , type 1 2 diabetes mellitus . 14 . Active untreated brain metastasis 15 . Pleural pericardial effusion grade 16 . Bone metastases 17 . Patients endocrine therapy appropriate ( i.e . life threaten metastatic disease ) . 18 . Patients require therapeutic anticoagulation ( Warfarin 1 mg port maintenance allow ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Breast</keyword>
	<keyword>Hormone receptor-positive metastatic breast cancer</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Faslodex</keyword>
	<keyword>MK-0646</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>BMS-354825</keyword>
	<keyword>Sprycel</keyword>
	<keyword>Adjuvant hormonal therapy</keyword>
</DOC>